71 related articles for article (PubMed ID: 19915982)
1. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2010 Mar; 10(1):1-8. PubMed ID: 19915982
[TBL] [Abstract][Full Text] [Related]
2. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
3. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent.
Zhou B; Wu LJ; Tashiro S; Onodera S; Uchiumi F; Ikejima T
Acta Pharmacol Sin; 2007 Jun; 28(6):803-10. PubMed ID: 17506939
[TBL] [Abstract][Full Text] [Related]
6. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.
Hasinoff BB; Patel D; O'Hara KA
Mol Pharmacol; 2008 Dec; 74(6):1722-8. PubMed ID: 18815214
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
10. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
[TBL] [Abstract][Full Text] [Related]
11. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Hasinoff BB; Patel D
Toxicol Appl Pharmacol; 2010 Dec; 249(2):132-9. PubMed ID: 20832415
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2020 Aug; 20(4):380-389. PubMed ID: 32124237
[TBL] [Abstract][Full Text] [Related]
13. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
14. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity.
Hasinoff BB
Toxicol Appl Pharmacol; 2010 Apr; 244(2):190-5. PubMed ID: 20045709
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
17. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of corneal neovascularization in rats by systemic administration of sorafenib.
Seo JW; Chung SH; Choi JS; Joo CK
Cornea; 2012 Aug; 31(8):907-12. PubMed ID: 22362003
[TBL] [Abstract][Full Text] [Related]
19. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
[TBL] [Abstract][Full Text] [Related]
20. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
